Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02692391 · ClinicalTrials.gov registry record · Phase 3
A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis
A Phase 3 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 3
- Development phase
- 42
- Enrollment target
NCT02692391 is a Phase 3 study that has completed, run by University of Pittsburgh. The registered enrollment target is 42 participants.
The verdict
NCT02692391, a Phase 3 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled pilot trial seeking to evaluate the efficacy of rectal indomethacin in abrogating systemic inflammation and subsequently organ failure and mortality in patients with AP and positive SIRS score.
Interventions
- DRUG Placebo
- DRUG Indomethacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2013-07 |
| Est. Completion | 2019-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02692391
The ClinicalTrials.gov registry entry for NCT02692391 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02692391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02692391 about?
NCT02692391 is a clinical study titled "A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis". This is a randomized, double-blind, placebo-controlled pilot trial seeking to evaluate the efficacy of rectal indomethacin in abrogating systemic inflammation and subsequently organ failure and mortality in patients with AP and positive SIRS score.
What is the current status of trial NCT02692391?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 42 participants. The study started on 2013-07. Estimated completion is 2019-12-30.
What interventions are being tested in trial NCT02692391?
The interventions under investigation include: Placebo (DRUG), Indomethacin (DRUG).
Who is sponsoring clinical trial NCT02692391?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.